MEMORANDUM

From:	Director, GCP	То:	Director, HTS	Date:	21 May 2021	
Our ref:		Attention:				
Your ref:	WHOHQ-E19-81-17	Through:				
Originator:	pb/skc	Subject:	MEETING OF THE 2	23rd EX	PERT	
			COMMITTEE ON SELECTION AND			
			USE OF ESSENTIAL	L MEDI	ICINES,	
			21 JUNE - 2 JULY 2021			
			21 JUNE - 2 JULI 20	141		

I would like to thank you for requesting the input of the AMR Global Coordination Department concerning the applications received for the inclusion of certain antibiotics and antifungal agents in the Model List of Essential Medicines (EML) and the Model List of Essential Medicines for Children (EMLc).


Our Department has reviewed the applications for the addition of the antibiotic cefiderocol for infections due to multidrug-resistant organisms in the EML and the addition of echinocandin antifungals for the treatment of invasive fungal infections in the EML and EMLc. Please find our full response to the proposed applications in the annex to this Memo.

Overall, we support the inclusion of cefiderocol in the EML and the echinocandin antifungals for the treatment of invasive fungal infections in the EML and EMLc, for the indications outlined in their respective applications.

We would like to bring the following aspects to the Committee's attention:

Access and affordability: Cefidorocol is a new antibiotic and the current pricing level of the echinacandins is still relatively high for generic products. Inclusion of these medicines in the EML would signal the need that they become accessible and affordable, globally. This will warrant establishing mechanisms and programmes to expand access and ensure appropriate use, particularly in low-income countries. Therefore, we encourage the EML Committee to consider access, affordability and stewardship for these lifesaving treatments.

Review of the EML for reserve antibiotics: Between July 2017 and September 2020 11 new antibiotics have been authorized by either FDA, EMA or both, out of which five have been considered by the EML committee so far. Another eight antibiotics targeting WHO priority pathogens are currently at the end stage of clinical development. In light of this, we recommend that



ENCL.: (1)



Approval for eDocument - HQ-2021-DOCS-eMemo-86628

Action	Action Taken By	Received On(UTC)	Action Taken On(UTC)	Comments	Attachments
Submitted	KOTUR CORLISS, Sandra	NA	21-May-2021 2:58 PM		
Cleared	BEYER, Peter	21-May-2021 3:00 PM	21-May-2021 3:04 PM		
Cleared	GETAHUN, Haileyesus	21-May-2021 3:08 PM	21-May-2021 3:13 PM		
Approved	ONDARI, Clive	21-May-2021 3:20 PM	21-May-2021 3:32 PM		